How can qHBsAg be used in response-guided therapy?

Patients who experience no decline in HBsAg from baseline at Week 12 have little chance of achieving a response to peg-IFN treatment^10,11

Response to peg-IFN treatment at Week 12^11,*

*Composite of HBeAg loss with HBV DNA <2,000 IU/mL or HBsAg loss at 6 months post-treatment.

HBsAg and HBV DNA levels at Week 12 identified HBeAg-negative patients with a very low chance of SVR^12,13